LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
27 funds hold it · Insiders net selling
Net selling: insiders sold $21.9M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $1K to $15K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 5, 2026
Period ending
Sep 30, 2026
Earnings per share
$2.36 expected
Estimates as of Nov 11, 2026
EPS expected
$2.46 to $2.75
Revenue expected
7 analysts
Last 30 days
Analysts raising estimates
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 5, 2026 | $2.39est. $2.36 | +1.46%beat | $493.0MSEC filing | +39.2%from $354.3M |
| Jun 30, 2026Reported Aug 6, 2026 | $2.28est. $1.82 | +25.53%beat | $481.0MSEC filing | +47.7%from $325.7M |
| Mar 31, 2026Reported May 11, 2026 | $1.60est. $1.52 | +5.26%beat | $376.7MSEC filing | +42.2%from $264.9M |
| Dec 31, 2025Reported Feb 17, 2026 | -$0.24est. $2.20 | -110.92%miss | $451.8MAlpha Vantage | +51.6%from $298.0M |
| Sep 30, 2025Reported Nov 3, 2025 | $1.72est. $1.63 | +5.52%beat | $354.3MSEC filing | +22.1%from $290.1M |
| Jun 30, 2025Reported Aug 5, 2025 | $1.54est. $1.27 | +21.26%beat | $325.7MSEC filing | +40.8%from $231.4M |
| Mar 31, 2025Reported May 6, 2025 | $1.11est. $0.95 | +16.84%beat | $264.9MSEC filing | +35.2%from $195.9M |
| Dec 31, 2024Reported Feb 18, 2025 | $1.26est. $1.16 | +8.73%beat | $298.0MAlpha Vantage | +29.5%from $230.0M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $451.8M | $376.7M | $481.0M | $493.0M |
| Cost of what it sold | $78.8M | $79.2M | $79.2M | $82.5M |
| Gross profit | $373.0M | $297.5M | $401.8M | $410.5M |
| What it spent | ||||
| Research and development | $31.9M | $25.6M | $27.7M | $27.8M |
| Sales and admin | $77.0M | $57.9M | $57.0M | $58.2M |
| Other operating costs | $23.4M | $29.5M | $29.5M | $29.5M |
| Total operating expenses | $132.3M | $113.0M | $114.2M | $115.5M |
| What was left | ||||
| Operating profit | $240.7M | $184.5M | $287.7M | $295.0M |
| Interest on debt | $4.9M | $5.5M | $5.6M | $6.0M |
| Profit before tax | -$100.8M | $180.3M | $284.9M | $290.6M |
| Tax | $40.7M | $30.3M | $55.0M | $43.6M |
| Net profit | -$141.6M | $150.0M | $229.9M | $247.0M |
| EBITDA | -$69.3M | $219.6M | $324.5M | $330.9M |
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Halozyme Stock Down Despite Q3 Earnings and Revenue Beat
Leans bearishNov 6Halozyme stock dips as Leerink downgrades on Q3 (HALO:NASDAQ)
BearishNov 6Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
NeutralNov 6Halozyme Therapeutics, Inc. (HALO) Projects Zero To Minimal Royalty Impact Through 2035
BullishNov 6Halozyme Q3 2026: Record Royalties Drive a Guidance Raise
BullishNov 6[Halozyme Therapeutics Q3 2026 Earnings Call] Halozyme Raises Guidance as Revenue Jumps 39% to $493M and Dutch Court Blocks Merck's Keytruda QLEX in Eight European Markets
BullishNov 6Halozyme falls 6% as raised guidance fails to impress investors By Investing.com
BearishNov 5Halozyme Therapeutics Q3 2026 Earnings Call Transcript
BullishNov 534 macro signals shaping HALO right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
